In recent years, medications have been developed that aim to influence Alzheimer’s in the brain.
A large review published in the Cochrane Database of Systematic Reviews, which compiles results from multiple studies, has taken a closer look at these effects.
The analysis is based on 17 studies involving around 20,000 participants. Patients were treated for 18 months and compared with a group receiving a placebo.
The results show that the medication only slows problems with memory, thinking, and daily activities to a very limited extent.
Also read: How to avoid excess liquid when frying mushrooms
Side effects such as brain swelling and small hemorrhages were also identified.
Criticism of methodology
However, several researchers believe the analysis has weaknesses.
According to a commentary in The Lancet, it is problematic that studies of different types of medication have been combined.
Some of the older drugs showed no effect, while newer treatments in certain studies have demonstrated better results. This may therefore present a misleading picture.
Also read: This happens in your body if you eat more protein than carbs
At the same time, diagnostic methods have improved over time.
This means that some earlier studies may have included patients who did not have Alzheimer’s disease.
Major considerations
Health authorities are still assessing whether the new treatments should be introduced. This requires significant resources and close monitoring of patients.
Researchers also point out the need to investigate other ways of treating the disease.
Also read: Pepsi Max may be linked to faster cognitive decline
Sources: Forskning.no, Cochrane Database of Systematic Reviews, and The Lancet.
Also read: Research: Timing of your meals may affect your weight